- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.02. | CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients | ||
| 28.01. | Cartesian Therapeutics announces FDA agreement for new trial | ||
| 28.01. | FDA approves new Alzheimer's treatment regimen | ||
| 27.01. | Vedanta Biosciences reveals Phase 2 VE303 results | ||
| 27.01. | Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX | ||
| 23.01. | Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment | ||
| 23.01. | Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol | ||
| 22.01. | Innovative Health Initiative launches a trial aimed at ending Crohn's Disease | ||
| 22.01. | AstraZeneca receives positive recommendations for lung cancer treatments | ||
| 21.01. | AlzeCure's NeuroRestore ACD856 to be presented at AD/PD 2025 | ||
| 21.01. | EC approves lazertinib in combination with amivantamab for NSCLC patients | ||
| 20.01. | UK sees 70% increase in phase I advanced therapy clinical trials in 2024 | ||
| 20.01. | Datapharm expands into US market through partnership with phactMI | ||
| 16.01. | Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials | ||
| 16.01. | Actinogen boosts trial with Cambridge Cognition's digital suite | ||
| 15.01. | Owlstone Medical announces $27 million USD first close in Series E financing round | ||
| 15.01. | Oxford Drug Design achieves in vivo validation for novel cancer treatment | ||
| 14.01. | Pheno Therapeutics granted trial authorisation for MS candidate | ||
| 14.01. | Grifols pioneers high-tech analysis of plasma bank to detect Parkinson's disease | ||
| 13.01. | AI set to revolutionise pharmaceutical R&D says GlobalData | ||
| 13.01. | Gilead and LEO Pharma partner to develop oral STAT6 program | ||
| 09.01. | New therapy hope for prostate cancer patients | ||
| 09.01. | NICE recommends olaparib for BRCA-mutated breast cancer treatment | ||
| 08.01. | Cambridge Cognition highlights positive Cantab results | ||
| 08.01. | Angelini Ventures co-leads Series A financing in Neumirna Therapeutics |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
